Estimation of adhesion to antiretroviral coformulated 3 in 1

Main Article Content

Bárbara Poliselo de Sá
Mariana Ribeiro Martins
Beatriz Böger
Frederico Alves Dias
Yanna Dantas Rattmann


Introduction: In order to stimulate adherence to antiretrovirals and minimize the risks of viral mutations and resistance to these drugs, the Ministry of Health (MS) started providing the 3-in-1 drug, a co-formulation of tenofovir (300 mg), lamivudine (300 mg) and efavirenz (600 mg), which innovates by the use of a single daily tablet. Objective: Estimating the adherence to antiretroviral drugs in the first line of HIV treatment. Methods: Verification of the frequency of monthly patient returns to a dispensary of antiretroviral drugs provided by MS. Results: Patients treated with the 3-in-1 medication were more assiduous and returned 65% higher at the dispensary. Conclusion: The introduction of 3-in-1 confirms that the simplification of therapeutic schemes is a measure that facilitates adherence to treatment. This generates the expectation of keeping individuals in the first line of treatment longer, delaying the need to resort to other more expensive therapeutic lines, with a higher number of drugs and associated risks.


Download data is not yet available.

Article Details

How to Cite
Sá, B. P. de, Martins, M. R., Böger, B., Dias, F. A., & Rattmann, Y. D. (2018). Estimation of adhesion to antiretroviral coformulated 3 in 1. ABCS Health Sciences, 43(3).
Original Articles
Author Biographies

Bárbara Poliselo de Sá, Curso de Farmácia, Laboratório de Saúde Pública e Ambiental, Universidade Federal do Paraná (UFPR) - Curitiba (PR)

Graduada em Farmácia

Mariana Ribeiro Martins, Curso de Farmácia, Laboratório de Saúde Pública e Ambiental, Universidade Federal do Paraná (UFPR) - Curitiba (PR)

Graduada em Farmácia

Beatriz Böger, Curso de Farmácia, Laboratório de Saúde Pública e Ambiental, Universidade Federal do Paraná (UFPR) - Curitiba (PR)

Farmacêutica, doutoranda em Ciências Farmacêuticas pela UFPR

Frederico Alves Dias, Centro de Medicamentos do Paraná (CEMEPAR), Secretaria de Estado da Saúde do Paraná, Curitiba (PR)

Farmacêutico, funcionário do CEMEPAR, responsável pela logística dos medicamentos antirretrovirais no Paraná

Yanna Dantas Rattmann, Curso de Farmácia, Laboratório de Saúde Pública e Ambiental, Universidade Federal do Paraná (UFPR) - Curitiba (PR)

Mestrado e doutorado em Farmacologia pela UFPR, com estágio na Université de Strasbourg-França. Atualmente, professora do Departamento de Saúde Comunitária da UFPR, Curso de Farmácia.


1. Centers for Disease Control and Prevention (CDC). HIV/AIDS: HIV transmission. Disponível em: Acesso em: 15 jun. 2017.

2. Brasil. Ministério da saúde. Departamento de Vigilância, Prevenção e Controle das IST, do HIV/AIDS e das Hepatites virais. Bol Epidemiológico HIVAids 2017. Disponível em: Acesso em: 13 fev. 2018.

3. Barros SG, Vieira-da-Silva LM. A terapia antirretroviral combinada, a política de controle da Aids e as transformações do Espaço Aids no Brasil dos anos 1990. Saúde Debate. 2017;41(spe 3):114-28.

4. Brasil. Presidência da República. Lei nº 9.313 de 13 de novembro de 1996. Dispõe sobre a distribuição gratuita de medicamentos aos portadores do HIV e doentes de AIDS. Disponível em: Acesso em: 15 jun. 2017.

5. Almeida SM, Pereira AP, Pedroso MLA, Ribeiro CE, Rotta I, Tang B, et al. Neurocognitive impairment with hepatitis C and HIV coinfection in Southern Brazil. J Neurovirol. 2018.

6. World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization, 2013.

7. Siddik AB, Haas A, Rahman MS, Aralaguppe SG, Amogne W, Bader J, et al. Phenotypic co-receptor tropism and Maraviroc sensitivity in HIV-1 subtype C from East Africa. Sci Rep. 2018;8(1):2363.

8. Haas AD, Zaniewski E, Anderegg N, Ford N, Fox MP, Vinikoor M, et al. Retention and mortality on antiretroviral therapy in sub-Saharan Africa: collaborative analyses of HIV treatment programmes. J Int AIDS Soc. 2018;21(2).

9. Garbin CAS, Gatto RCJ, Garbin AJI. Adesão à terapia antirretroviral em pacientes HIV soropositivos no Brasil: uma revisão da literatura. Arch Health Invest. 2017;6(2):65-70.

10. Hessol NA, Schwarcz SK, Hsu LC, Shumway M, Machtinger EL. Gender differences in causes of death among persons with HIV/AIDS in San Francisco, California, 1996-2013. Int J STD AIDS. 2018;29(2):135-46.

11. Gangcuangco LMA, Sawada I, Tsuchiya N, Do CD, Pham TTT, Rojanawiwat A, et al. Regional Differences in the Prevalence of Major Opportunistic Infections among Antiretroviral-Naïve Human Immunodeficiency Virus Patients in Japan, Northern Thailand, Northern Vietnam, and the Philippines. Am J Trop Med Hyg. 2017;97(1):49-56.

12. Orrell C, Cohen K, Leisegang R, Bangsberg DR, Wood R, Maartens G. Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poorsetting: which best predicts virological and resistance outcomes? AIDS Res Thern. 2017;14:20.

13. Delicio AM, Milanez H, Amaral E, Morais SS, Lajos GJ, Silva JL, et al. Mother-to-child transmission of human immunodeficiency virus in aten years period. Reprod Health. 2011;8:35.

14. Girma M, Wendaferash R, Shibru H, Berhane Y, Hoelscher M, Kroidl A. Uptake and performance of prevention of mother-tochild transmission and early infant diagnosis in pregnant HIVinfected women and their exposed infants at seven health centres in Addis Ababa, Ethiopia. Trop Med Int Health. 2017;22(6):765-75.

15. Brasil. Ministério da Saúde. Departamento de Vigilância, Prevenção e Controle das IST, do HIV/Aids e das Hepatites Virais. Protocolo clínico e diretrizes terapêuticas para manejo da infecção pelo HIV em adultos. Brasília: Ministério da Saúde, 2015.

16. Inocêncio LA, Pereira AA, Sucupira MCA, Fernandez JCC, Jorge CP, Souza DFC, et al. Brazilian Network for HIV Drug Resistance Surveillance: a survey of individuals recently diagnosed with HIV. J Int AIDS Soc. 2009;12:20.

17. Hileman CO, Funderburg NT. Inflammation, Immune Activation, and Antiretroviral Therapy in HIV. Curr HIV/AIDS Rep. 2017;14(3):93-100.

18. Salleh NAM, Richardson L, Kerr T, Shoveller J, Montaner J, Kamarulzaman A, et al. A longitudinal analysis of daily pill burden and likelihood of optimal adherence to antiretroviral therapy among people living with HIV Who Use Drugs. J Addict Med. 2018.